Coronavirus Disease (COVID-19) Clinical Trial
Official title:
Aerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus: a Dilemma
There is little information on the characteristics of airborne severe acute respiratory syndrome coronavirus containing aerosols, their concentration, or their infectivity.The aim was to determine airborne severe acute respiratory syndrome coronavirus transmission, their infectivity in different areas such as patient's room and in medical staff área.
The Corona Virus Disease 2019 is rapidly spreading throughout the world. Aerosol is a potential transmission route. The transmission of severe acute respiratory syndrome coronavirus in humans is thought to be via at least 3 sources: 1) inhalation of liquid droplets produced by and/or 2) close contact with infected persons and 3) contact with surfaces contaminated with severe acute respiratory syndrome coronavirus. There are many respiratory diseases spread by the airborne route such as tuberculosis, measles and chickenpox. Several studies suggested that airborne spread may have played an important role in the transmission of that disease. At present, there is little information on the characteristics of airborne severe acute respiratory syndrome coronavirus containing aerosols, their concentration, or their infectivity. The aim was to determine airborne severe acute respiratory syndrome coronavirus 2 transmission, their infectivity in in different areas such as patient's room and in medical staff area. Methods Cross sectional study of samples from environmental of patient´s room, and medical staff area. Samples will be taken of air using microbial air monitoring systems, and from different surfaces of patient's room and medical staff area, such as computers, mouse and personal protective equipment using cotton swabs. Viral RNA will be determined using Real-Time-Polymerase-Chain Reaction. In positive samples infectiveness will be determined by cell culture under biosecurity conditions. Statistical analysis will be performed to determine prevalence of positive samples and positive cell culture whit STATA version 15.1. informed consent will be obtained from all participants ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04583982 -
ImmuneSense™ COVID-19 Study
|
||
| Terminated |
NCT04569786 -
Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)
|
Phase 1 | |
| Completed |
NCT04575597 -
Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)
|
Phase 2/Phase 3 | |
| Terminated |
NCT04575584 -
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04572360 -
Cardiorespiratory Exercise & Chinese Medicine for Rehabilitation of Discharged Coronavirus Disease (COVID-19) Patients
|
N/A | |
| Recruiting |
NCT04885361 -
To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults
|
Phase 1 | |
| Not yet recruiting |
NCT04360122 -
Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19
|
Phase 3 | |
| Completed |
NCT05119855 -
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
|
Phase 3 | |
| Completed |
NCT04558307 -
Feasibility of Rapid COVID-19 Testing in Disadvantaged Populations
|
||
| Recruiting |
NCT04584606 -
Ain Shams University Experience: Clinical Determinants of Hospitalized COVID-19 Patients
|
||
| Completed |
NCT04677660 -
A Study of TAK-919 in Healthy Japanese Adults (COVID-19)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04280588 -
Fingolimod in COVID-19
|
Phase 2 | |
| Completed |
NCT04941144 -
Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination
|
||
| Terminated |
NCT04498247 -
A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)
|
Phase 1/Phase 2 | |
| Completed |
NCT04939428 -
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
|
Phase 3 | |
| Withdrawn |
NCT04892888 -
Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms
|
||
| Completed |
NCT04348214 -
Screening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hospitals
|
||
| Not yet recruiting |
NCT04350931 -
Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19
|
Phase 3 | |
| Not yet recruiting |
NCT04346043 -
To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database
|
||
| Not yet recruiting |
NCT04348877 -
Plasma Rich Antibodies From Recovered Patients From COVID19
|
N/A |